
14/02/2025
Finnish startup secures €2.3M to advance stem cell therapy for corneal blindness
Tampere-based biotech startup StemSight has raised €2.3 million in funding to advance its stem cell-based therapy for limbal stem cell deficiency (LSCD), a condition that leads to corneal blindness. The investment, led by Voima Ventures and supported by Finnish family offices (Stephen Industries Inc. & Biothom Oy), private investors, and Business Finland, will fund preclinical studies, R&D, and manufacturing pilots to prepare for clinical trials. StemSight is developing an off-the-shelf therapy using induced pluripotent stem cells (iPS cells) as an alternative to corneal transplants, addressing the shortage of donor corneas, which affects 12.7 million people globally. LSCD, often caused by burns or injuries, currently lacks effective treatment for many patients, making the development of scalable cell therapies a potential step forward in vision care.
https://arcticstartup.com/stemsight-raises-e2-3-million/